| Term es nes pval sidak fdr geneset_size leading_edge leading_edge_size |
| Sphingolipid pathway 0.886933381691622 3.2068198912753267 0.0013421099475308 0.5520711192384767 0.1729996636702148 12 Q13510,O15269,Q16739,P04062,Q8N5B7,Q16880,Q06136,O95470,Q96G23 9 |
| Electron transport chain oxphos system in mitochondria 0.5926911048405091 3.103715759541535 0.0019110683424186 0.6814297504343076 0.1729996636702148 52 O14949,Q9Y6M9,O43676,P21912,P31930,O96000,Q9UDW1,O95168,P14406,P24539,O75964,O75306,P03886,P13073,P00403,P06576,P22695,P20674,Q7KZN9,P51970,O75880,P12235,O14548 23 |
| Sphingolipid metabolism integrated pathway 0.9118489181877442 3.0592560682431267 0.0022188740314601 0.7350888915899535 0.1729996636702148 9 Q13510,O15269,Q16739,Q8N5B7,Q06136,O95470,Q96G23 7 |
| Sphingolipid metabolism overview 0.9111546709419572 2.907902875116867 0.003638613260626 0.8869425261172323 0.1729996636702148 8 Q13510,O15269,Q16739,Q06136,O95470,Q96G23 6 |
| Mitochondrial complex iv assembly 0.8406634898118819 2.8930049375927176 0.0038157529853317 0.8983464507068692 0.1729996636702148 11 Q7KZN9,P13073,P00403,Q8N8Q8,P14406,P20674,Q9Y2R0 7 |
| Sphingolipid metabolism in senescence 0.7962906432646116 2.8690247655743804 0.004117395583522 0.9151852189796698 0.1729996636702148 13 Q13510,P16278,Q16739,P04062,Q06136,Q96G23 6 |
| Nonalcoholic fatty liver disease 0.5632805787550452 2.8523699525794184 0.0043394564465772 0.9257740701325744 0.1729996636702148 52 O14949,Q9Y6M9,P13073,O43676,P21912,P00403,Q9P0J0,P31930,O96000,Q9UDW1,P22695,O95168,P14406,O75306,P20674,O14548,Q86Y39,P49327 18 |
| Cholesterol metabolism with bloch and kandutschrussell pathways 0.6181025062908037 2.561192208014064 0.0104313626864915 0.9981091297648792 0.2310353661674803 25 Q9UBM7,Q15800,Q14739,Q16850,P53602,Q9BWD1,P48449,P37268,P35610,P04035,Q15392,Q14534,P49327,Q15125 14 |
| Mitochondrial complex iii assembly 0.7854733595690441 2.5412679602015538 0.0110451233439357 0.9986952332968888 0.2358922771311982 10 O14949,P08574,P31930,P22695,Q9BRT2,Q9UDW1 6 |
| Ferroptosis 0.6149641479031792 2.3871894634342468 0.0169777391733652 0.999964282183965 0.2674140237990623 21 Q9UKU0,P16435,P45880,P09601,P37268,Q9Y277,P04035 7 |
| Cholesterol biosynthesis with skeletal dysplasias 0.8471711903592806 2.362805501751325 0.0181371856254208 0.9999823645770056 0.2674140237990623 6 Q15392,Q14739,Q16850,Q15125 4 |
| Overlap between signal transduction pathways contributing to lmna laminopathies 0.6531198671533908 2.3059451923108942 0.0211136949972234 0.9999971299659028 0.2933851285058968 15 P50402,P42167,O75844,P55209,O60725 5 |
| Metabolism of spingolipids in er and golgi apparatus 0.9151119402985064 2.286964506465978 0.0221978948892824 0.999998520623154 0.2933851285058968 5 Q10472,O95470,Q06136,Q16739 4 |
| Intracellular trafficking proteins involved in cmt neuropathy 0.7404346954055484 2.2449076026257218 0.0247740647836207 0.999999694553632 0.2938537194646291 9 P07196,Q9NR77,Q8TB36,Q6UWE0 4 |
| Metapathway biotransformation phase i and ii 0.5896151171998274 2.2189265953367303 0.0264917188327982 0.99999989355854 0.2964618496190351 21 Q6UW02,Q7LGA3,Q16850,P07099,Q8NCH0 5 |
| Oxidation by cytochrome p450 0.8070904630235106 2.1850304795364863 0.0288866118652693 0.9999999755980225 0.2964618496190351 6 O43169,Q6UW02,Q16850 3 |
| Degradation pathway of sphingolipids including diseases 0.8018818352546563 2.1616629489246413 0.030644165507029 0.9999999917401772 0.2964618496190351 6 P16278,P17900,P06280,O43681 4 |
| Statin inhibition of cholesterol production 0.7710239005716305 2.137973764962428 0.0325188725712797 0.9999999974045288 0.2964618496190351 7 P37268,Q8WTV0,Q14534,P04035 4 |
| Glycosaminoglycan degradation 0.7850233102687662 2.085614612301929 0.037013546648879 0.9999999998397248 0.3150983296323673 6 P16278,P54802,P34059 3 |
| Copper homeostasis 0.7591392262757057 2.082247900831919 0.037319832006003 0.9999999998674892 0.3150983296323673 7 P05067,O43819,P35670,Q04656 4 |
| Allograft rejection 0.7046052812098311 2.0641156280967947 0.0390067545471097 0.999999999953574 0.3239727669329395 9 P10321,P08670,Q9BY49,P08183,P49327 5 |
| 7oxoc and 7betahc pathways 0.6849908230321317 2.029539056636415 0.042403415091673 0.9999999999944128 0.3384362766871859 10 Q9UBM7,O15118,P61916,Q15125 4 |
| Kennedy pathway from sphingolipids 0.8452748234046477 2.003560562756072 0.0451171539641492 0.9999999999989764 0.3498113693425534 5 Q9UG56,P35790,O95470 3 |
| Familial partial lipodystrophy fpld 0.6841498637078105 1.8364868001902488 0.0662856925433896 1.0 0.4333881084372532 8 O60725,O75844 2 |
| Progeriaassociated lipodystrophy 0.6378352171348486 1.778801415314862 0.0752723250836235 1.0 0.4528267482024692 10 O60725,O75844 2 |
| Mitochondrial immune response to sarscov2 0.6322867569420156 1.688000092315287 0.0914112112201992 1.0 0.529438248557106 9 Q9Y6M9,Q9BQ95,Q86UT6 3 |
| Riboflavin and coq disorders 0.6854607819085909 1.6240897766679316 0.1043566495441243 1.0 0.5473912402439215 6 O75208,Q8NI60,Q16134 3 |
| Type i collagen synthesis in the context of osteogenesis imperfecta 0.584675481445417 1.6138707789291658 0.1065554580872554 1.0 0.5473912402439215 12 O15460,Q5JRA6,Q96AY3,Q32P28,P13674,O75718 6 |
| Influence of laminopathies on wnt signaling 0.5958511484669405 1.6117335169431015 0.1070199408326599 1.0 0.5473912402439215 11 O60725,P50402,O75844 3 |
| Cholesterol biosynthesis pathway 0.5682149527595817 1.600973463091137 0.1093827968478313 1.0 0.5496715337395223 13 Q9UBM7,Q15800,P53602,Q16850,P48449,P37268,P04035,Q14534 8 |
| Proteoglycan biosynthesis 0.7442978568604969 1.5792745527399117 0.1142730960967135 1.0 0.5546197851567196 5 Q8NCH0,Q8TB61 2 |
| Mitochondrial complex i assembly model oxphos system 0.4809263300836481 1.5776800777455828 0.1146391253626821 1.0 0.5546197851567196 26 Q96CU9,P03886,Q9Y6M9,O43676,P51970,Q9P0J0,O96000,O95168,O75306 9 |
| Adipogenesis 0.5640434832354001 1.5760912663804012 0.1150047715040689 1.0 0.5546197851567196 13 P49327,P02545,O75844,P43490 4 |
| Oxidative phosphorylation 0.4745226963758415 1.5676018258281963 0.1169740857521952 1.0 0.5596040262385021 31 P03886,Q9Y6M9,P24539,O75787,P06576,Q15904,O75964,O96000,O95168,O75306,Q86Y39 11 |
| Vasopressinregulated water reabsorption 0.523934603991843 1.5434964575089745 0.1227103663490705 1.0 0.5732874927870638 16 Q9UJW0,Q13409,Q13561 3 |
| Triacylglyceride synthesis 0.7153619169925278 1.4550460861897645 0.1456565032760299 1.0 0.6102698287859607 5 Q9HCL2,O00116,Q9NUQ2 3 |
| Acquired partial lipodystrophy barraquersimons syndrome 0.7152741203011697 1.4546677714760097 0.1457612589514147 1.0 0.6102698287859607 5 P20700,O60725,P02545 3 |
| Ccl18 signaling pathway 0.5865536109381544 1.4430881401228564 0.1489956438173081 1.0 0.6102698287859607 9 P08670,P07196 2 |
| Alzheimers disease and mirna effects 0.3682431183248354 1.3097929896196987 0.1902658753569686 1.0 0.6951682416065309 84 Q13509,Q9NSK0,P49721,Q92542,P12235,P21796,P12236,P45880,Q8NE86,P28072,Q9Y277,Q96IX5,Q9NQC3,P05067,O95197,P49327,P16615,P20618 18 |
| Folate metabolism 0.4795473797861357 1.2195230999959572 0.2226457137570872 1.0 0.7219857299678484 15 P00374 1 |
| Glycerophospholipid biosynthetic pathway 0.5641580105578995 1.218938307132867 0.2228676088252892 1.0 0.7219857299678484 8 Q9HCL2,Q9BTU6,O00116,O95674 4 |
| Photodynamic therapyinduced nfe2l2 nrf2 survival signaling 0.6565398742954806 1.200327443159464 0.230012195636208 1.0 0.7304487005734978 5 P09601 1 |
| Vitamin d metabolism 0.9111249223119908 1.1957316445651445 0.2318012982722708 1.0 0.7304487005734978 3 P04062,P38435 2 |
| Familial hyperlipidemia type 4 0.7067119683425888 1.1860860494203993 0.2355883192082961 1.0 0.7343096011199655 4 Q9UBV2 1 |
| Alzheimers disease 0.3567503655987871 1.182825568329299 0.2368782851325188 1.0 0.7343096011199655 83 Q13509,Q9NSK0,P49721,Q92542,P12235,P21796,P12236,P45880,Q8NE86,P28072,Q9Y277,Q9NQC3,P05067,O95197,P49327,P16615,P20618 17 |
| Inclusion body myositis 0.9189189189189172 1.169906944327413 0.2420384190037467 1.0 0.7347156069250791 2 P05067 1 |
| Striated muscle contraction pathway 0.7001651900268495 1.158870364851321 0.2465090302634673 1.0 0.7384990919928897 4 P08670 1 |
| Camkk2 pathway 0.5343870335072883 1.15882634226605 0.246526977689317 1.0 0.7384990919928897 9 P09601,O76024 2 |
| Glycerolipids and glycerophospholipids 0.5850605232525392 1.1420962522726517 0.253414013088745 1.0 0.7480239213924504 6 Q9HCL2,Q9UG56 2 |
| Endothelin pathways 0.5652892472602067 1.1313289870928438 0.2579166481655535 1.0 0.7496672701746805 7 P42892,P16615 2 |
| Amyotrophic lateral sclerosis als 0.5279116760252895 1.1233272403668628 0.2612985387261284 1.0 0.7543374538146478 9 P07197 1 |
| Genes related to primary cilium development based on crispr 0.4672101238519108 1.0589857197006949 0.2896062833247916 1.0 0.7627610982380683 14 Q96J42,O95684,Q9Y496,Q8NCM8,Q10713 5 |
| Cellular proteostasis 0.6755542406769759 1.0568230809565622 0.2905923383961464 1.0 0.7627610982380683 4 Q99471 1 |
| Eicosanoid synthesis 0.8696375675644052 1.050377237939814 0.2935447065709489 1.0 0.7627610982380683 3 P09960 1 |
| Oxysterols derived from cholesterol 0.531705831395265 1.0485436962396228 0.2943881811434514 1.0 0.7627610982380683 8 Q9UBM7,Q15125 2 |
| Omega3 omega6 fatty acid synthesis 0.5589804473956331 1.016020414646309 0.3096196652151006 1.0 0.7766022735652484 6 O15254 1 |
| Glycosylation and related congenital defects 0.5419195221010453 1.0136500873635383 0.3107497485758981 1.0 0.7766022735652484 7 Q9BT22 1 |
| G protein signaling pathways 0.4407820477184508 0.9914880851352912 0.3214473074955943 1.0 0.7910513986928618 16 P50148,P63218,O43572,O43823,Q9UBI6,P04899,P63096 7 |
| Apoptosis modulation by hsp70 0.8473812442438886 0.9732863094122846 0.3304110248038481 1.0 0.8097778394782834 3 O95831 1 |
| Nanomaterial induced apoptosis 0.8521279900590233 0.9243811385705544 0.3552879113622329 1.0 0.8330997904661711 2 O95831 1 |
| Regulation of wnt bcatenin signaling by small molecule compounds 0.6414723263021247 0.9167555660993216 0.3592707413942873 1.0 0.8330997904661711 4 P49841 1 |
| Nuclear receptors in lipid metabolism and toxicity 0.8437402920161536 0.8942574379113093 0.3711841668200848 1.0 0.8330997904661711 2 P28288 1 |
| Nephrotic syndrome 0.4375455354465675 0.870667022676252 0.3839359895182375 1.0 0.8387001078121608 14 O75844,Q9BT22,Q14108 3 |
| 1q211 copy number variation syndrome 0.4660197078208369 0.8673827438930655 0.3857323335263183 1.0 0.8387001078121608 11 Q9NPH0 1 |
| S1p receptor signal transduction 0.5110969179197825 0.8592293575899118 0.3902139894838394 1.0 0.8387001078121608 7 Q13510,P04899 2 |
| Prostaglandin and leukotriene metabolism in senescence 0.8029832193909099 0.8223901905997433 0.4108548604469089 1.0 0.840864257177043 3 P50148,P09960 2 |
| Cerebral organic acidurias including diseases 0.5652941842098268 0.8070232463032627 0.4196530903025817 1.0 0.840864257177043 5 Q9H9P8 1 |
| Ketogenesis and ketolysis 0.5639874447886363 0.8014934673601216 0.4228460244380647 1.0 0.840864257177043 5 P23786,P53985 2 |
| Celltype dependent selectivity of cck2r signaling 0.8027337682510096 0.7503249971230251 0.453058991012381 1.0 0.8573711285614046 2 P50148 1 |
| Intraflagellar transport proteins binding to dynein 0.4524301094164847 0.6377865160046219 0.5236126582225813 1.0 0.8997711770606427 8 Q13409 1 |
| Pkcgamma calcium signaling pathway in ataxia 0.7411239796136937 0.6220653116003171 0.5338989231922415 1.0 0.9045624769086364 3 P50148 1 |
| Regulation of apoptosis by parathyroid hormonerelated protein 0.7327398623985895 0.5961335648195261 0.5510860029255729 1.0 0.9121452673868358 3 Q07820 1 |
| Mevalonate pathway 0.4686260531831787 0.5899157891489376 0.5552471080870391 1.0 0.9121452673868358 6 Q9BWD1,P53602,P04035 3 |
| Spinal cord injury 0.3752578479946757 0.5771942614030374 0.5638082332278533 1.0 0.9121452673868358 17 P08670,P14174,Q9NQC3 3 |
| Omega9 fatty acid synthesis 0.4615338981519101 0.5580228287431545 0.5768287955576306 1.0 0.9121452673868358 6 P33121,P49327 2 |
| Apoptosis modulation and signaling 0.4112551124932855 0.5575493913530797 0.5771521230263206 1.0 0.9121452673868358 11 O95831,P49327,Q07820 3 |
| Wnt signaling pathway and pluripotency 0.3755458515283784 0.5414294864255229 0.5882115878548455 1.0 0.9154075931601786 15 P30153,P30154,Q16537,P04637,P56545,P43034,P35222,O60716,P63151,Q9H0H5,P01130,Q15257,P05771,P49841 14 |
| Envelope proteins and their potential roles in edmd physiopathology 0.3725736806792619 0.5227303243600012 0.60116193252943 1.0 0.9154075931601786 15 P50402,Q14739 2 |
| Notch signaling 0.4273705997045094 0.5135398940836982 0.6075737119457594 1.0 0.9154075931601786 8 Q92542 1 |
| Purinergic signaling 0.7003629016848782 0.4994919189276752 0.6174328783401226 1.0 0.9161907226982464 3 P04899 1 |
| Tryptophan metabolism 0.3628840609464613 0.4623939996969366 0.6437988014644138 1.0 0.9380161583002656 15 Q15392,P51648 2 |
| Vitamin dsensitive calcium signaling in depression 0.4283621502259338 0.4619836275677961 0.6440930614767562 1.0 0.9380161583002656 7 P20020,Q8NB78 2 |
| Calcium regulation in cardiac cells 0.337253194865155 0.4589659413908261 0.6462586241132264 1.0 0.9380161583002656 25 P50148,P63096,P63218,Q9UBI6,P04899,P20020,P10644,P16615 8 |
| Sarscov2 and covid19 pathway 0.5159030207713089 0.436737736831827 0.6623015582619147 1.0 0.944215763583068 4 Q8WTV0 1 |
| Mirna regulation of p53 pathway in prostate cancer 0.7005281143212174 0.4286241289802543 0.6681967830004103 1.0 0.94544508086351 2 O14681 1 |
| Lncrnamediated mechanisms of therapeutic resistance 0.7005281143212078 0.4286241289802281 0.6681967830004294 1.0 0.94544508086351 2 P08183 1 |
| Liver x receptor pathway 0.6949363156259598 0.4131368665310362 0.6795063401720607 1.0 0.9458164937991116 2 P49327 1 |
| Mevalonate arm of cholesterol biosynthesis pathway 0.3838362185347521 0.4099441638782209 0.681846907344605 1.0 0.9458164937991116 11 P53602,Q9BWD1,P37268,P35610,P04035 5 |
| Oligodendrocyte specification and differentiation leading to myelin components for cns 0.692451071761408 0.4063392846704122 0.684493324281672 1.0 0.9458164937991116 2 Q99640 1 |
| Mitochondrial long chain fatty acid betaoxidation 0.3687207430361464 0.3992022204784591 0.68974420723417 1.0 0.9482000825885832 13 Q16836,Q9BY49,P49748,P50416,P23786 5 |
| Interactions between loxl4 and oxidative stress pathway 0.651122560042659 0.3654102446095283 0.714805195113104 1.0 0.9566544791605224 3 Q9BQ95 1 |
| Photodynamic therapyinduced ap1 survival signaling 0.4063535830012567 0.3650270366353592 0.7150912243892198 1.0 0.9566544791605224 7 Q07820 1 |
| Sting pathway in kawasakilike disease and covid19 0.6654240447343791 0.3360031162234184 0.7368685165511437 1.0 0.9698455128440094 2 Q86UT6 1 |
| Vitamin d receptor pathway 0.3659547989023967 0.3183402821954533 0.7502268315725551 1.0 0.9729153020875289 11 Q96KA5,P08183,Q92604,Q5VV42 4 |
| Nocgmppkg mediated neuroprotection 0.4003790995039863 0.3019712814079501 0.7626739557044444 1.0 0.9808151086263608 6 P30536 1 |
| Ppar signaling pathway 0.3320154522932947 0.2891794725524163 0.7724440396311758 1.0 0.986581307463142 16 Q9UKU0,P23786,O15254 3 |
| Nsp1 from sarscov2 inhibits translation initiation in the host cell 0.3454510990346245 0.2730863563174599 0.7847868343448752 1.0 0.9880053198699692 13 P56537,P55010 2 |
| Airway smooth muscle cell contraction 0.4129353233830756 0.2313656192306063 0.8170307724646189 1.0 1.0 5 P50148,O75116,P31150,Q13464 4 |
| Hedgehog signaling pathway wp47 0.6185150667909212 0.2310687435672734 0.817261397083112 1.0 1.0 2 O00422 1 |
| Pi3kaktmtor signaling pathway and therapeutic opportunities 0.3779160186625159 0.2196106316384069 0.826174410691485 1.0 1.0 6 Q15118,Q15382,O00459,P42345,P49841 5 |
| Steroid biosynthesis 0.5860783095090148 0.2187735636363505 0.8268264411940507 1.0 1.0 3 P51659,P56937 2 |
| Circadian rhythm genes 0.2948056643659802 0.1813122046647168 0.8561225268584631 1.0 1.0 45 Q14103,Q03164,P43490,Q9BWF3,Q9NRV9,P23246,P50416,P49327,P54802 9 |
| Vitamin b12 disorders 0.5647113989790935 0.1794388144031469 0.8575931564566366 1.0 1.0 3 Q99707 1 |
| Srebf and mir33 in cholesterol and lipid homeostasis 0.3556690159819606 0.1668633040341822 0.8674776074145347 1.0 1.0 7 P04035 1 |
| Vitamin d in inflammatory diseases 0.4211998756605569 0.1621665967050354 0.8711746635488749 1.0 1.0 4 O60244,O14920,Q16539 3 |
| Extracellular vesiclemediated signaling in recipient cells 0.5675675675675569 0.1441673735186646 0.885368303922317 1.0 1.0 2 P35222 1 |
| Ciliary landscape 0.2847030986061986 0.1320391451140306 0.8949533294691947 1.0 1.0 101 Q14566,P06280,P16278,P08670,Q13409,P07197,O15173,P10619,P07196,Q92600 10 |
| Mecp2 and associated rett syndrome 0.2961312619567233 0.1274452042624256 0.8985880400799129 1.0 1.0 20 P52597,Q03518,P35637,P31943 4 |
| Nodlike receptor nlr signaling pathway 0.5461323392357743 0.1161777068883279 0.9075117044243308 1.0 1.0 2 O14920 1 |
| Neural crest differentiation 0.3234178608939402 0.1103174324567549 0.9121576325429486 1.0 1.0 10 Q9NR77,Q04721 2 |
| Supression of hmgb1 mediated inflammation by thbd 0.5209692451071674 0.0894708997521385 0.9287076794457576 1.0 1.0 2 O14920 1 |
| 3q29 copy number variation syndrome 0.3113362419643374 0.0854118148350414 0.9319340006076032 1.0 1.0 12 O95684,Q12959,Q8NCM8 3 |
| Preimplantation embryo 0.3294397502277814 0.0824182752904521 0.9343141039089098 1.0 1.0 7 Q92945,Q99729 2 |
| Fibrin complement receptor 3 signaling pathway 0.4886610748679689 0.0640267732417896 0.9489489085759082 1.0 1.0 2 O14920 1 |
| Aryl hydrocarbon receptor pathway wp2873 0.3407960199004871 0.0525853535798769 0.9580622869740592 1.0 1.0 5 O00170,Q16543,P07900,P12931 4 |
| Burn wound healing 0.3131141923940147 0.0475385983785212 0.9620839680384652 1.0 1.0 8 P31949,P08670,O60885 3 |
| Robo4 and vegf signaling pathways crosstalk 0.4459291485394746 0.0437806334500397 0.9650792645484828 1.0 1.0 3 O94813,P12931 2 |
| Sars coronavirus and innate immunity 0.443305374339836 0.0420623515524661 0.9664489927021056 1.0 1.0 2 P42224 1 |
| Tcell antigen receptor tcr pathway during staphylococcus aureus infection 0.3017595704419529 0.0379586029527634 0.9697206882812244 1.0 1.0 11 O95433 1 |
| Congenital generalized lipodystrophy cgl 0.425598011804893 0.0368368153574253 0.9706151195477256 1.0 1.0 2 P31751 1 |
| Serotonin and anxietyrelated events 0.4209381795588625 0.0357066818336745 0.971516242618372 1.0 1.0 2 P05771 1 |
| Serotonin and anxiety 0.4210689869484284 0.0308768526610087 0.9753677500203112 1.0 1.0 3 Q06787,P05771 2 |
| Glial cell differentiation 0.3901832867350105 0.0302956720451115 0.97583124819776 1.0 1.0 2 P09543 1 |
| Mir124 predicted interactions with cell cycle and differentiation 0.3690587138862902 0.028150908669271 0.9775417908959104 1.0 1.0 2 Q13131 1 |
| Folatealcohol and cancer pathway hypotheses 0.351662006834422 0.0270334018234008 0.9784330929577 1.0 1.0 2 Q99707 1 |
| Vitamin b6dependent and responsive disorders 0.3451382416899644 0.026727010541522 0.9786774695275768 1.0 1.0 2 P49419 1 |
| Hepatitis b infection 0.2744791732291388 0.0177261202555172 0.9858573429690292 1.0 1.0 21 Q9Y277,Q15904 2 |
| Mammary gland development pathway pregnancy and lactation stage 3 of 4 0.3279452906434619 0.0144281550153488 0.9884883972720044 1.0 1.0 4 P06753,P18031,P61201 3 |
| Tgfbeta signaling pathway 0.2763450636722837 0.0122956693062026 0.9901897224884544 1.0 1.0 33 Q96PU5 1 |
| Ovarian infertility 0.338719701678068 0.0111308847703459 0.991119022281195 1.0 1.0 3 P11802,Q8WXH0 2 |
| Apoptosisrelated network due to altered notch3 in ovarian cancer 0.2833772936784865 0.0094697528602808 0.9924443433254526 1.0 1.0 14 P05067 1 |
| Hippoyap signaling pathway 0.2886886264760802 0.0082817829926086 0.9933921687506082 1.0 1.0 3 P27348,Q13043 2 |
|
|
